HER2 gene alterations, both mutations and gene amplifications, are markedly less frequent in ESCC than in EAC, thus indicating that HER2 targeting is a potential therapy only in a minority of ESCC patients. Here, ERBB2 is linked to esophageal squamous cell carcinoma.